Skip to content

Study · Non-randomized trial · n = 6 · 2004

8 results

Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment.

Miki T, Nakatsuka K, Naka H, Masaki H, Imanishi Y, Ito M, Inaba M, Morii H, Nishizawa Y

Journal of bone and mineral metabolism1 Jan 2004Cited by 33 (Europe PMC)

PMID15490267 (opens in a new tab)DOI10.1007/s00774-004-0525-z (opens in a new tab)PepBankPUB-15490267
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In primary osteoporosis patients receiving hPTH, biopsy sections showed no qualitative bone or marrow abnormalities.

    In plain wordsIn patients receiving hPTH, bone biopsies showed no abnormal bone or marrow tissue.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableQualitative bone and marrow abnormalities
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 units once weekly · subcutaneous · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Examination of thin hard-tissue sections revealed no qualitative abnormalities of bone tissue or bone marrow cavity, such as osteomalacia, woven bone, or osteitis fibrosa, precluding the contribution of qualitatively abnormal tissue elements to any changes of LBMD in response to hPTH 1-34 administration.
  2. 02HumanNon-randomized trialEfficacy outcome

    In primary osteoporosis patients, biopsy measurements showed a tendency toward increased bone volume after hPTH versus baseline.

    In plain wordsIn patients with primary osteoporosis, bone volume tended to increase after hPTH compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Direction not reportedHistomorphometric bone volume
    Study

    n = 6

    Comparator
    Preadministration measurements
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 units once weekly · subcutaneous · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Histomorphometric measurement in the second biopsy revealed a tendency for an increase of bone volume, a significant increase of osteoid surface, and a tendency for an increase in other parameters of bone formation, compared with values obtained in the preadministration biopsy.
  3. 03HumanNon-randomized trialEfficacy outcome

    In primary osteoporosis patients, hPTH significantly increased osteoid surface compared with preadministration biopsy measurements.

    In plain wordsIn patients with primary osteoporosis, hPTH increased new unmineralized bone surface compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseOsteoid surface
    Study

    n = 6

    Comparator
    Preadministration measurements
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 units once weekly · subcutaneous · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Histomorphometric measurement in the second biopsy revealed a tendency for an increase of bone volume, a significant increase of osteoid surface, and a tendency for an increase in other parameters of bone formation, compared with values obtained in the preadministration biopsy.
  4. 04HumanNon-randomized trialEfficacy outcome

    In primary osteoporosis patients, three-dimensional analysis showed significantly increased bone volume after hPTH.

    In plain wordsIn patients with primary osteoporosis, hPTH increased bone volume compared with baseline in three-dimensional images.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseThree-dimensional bone volume
    Study

    n = 5

    Comparator
    Preadministration measurements
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 units once weekly · subcutaneous · 1 yearAs given in this study (human).

    Source sentences

    Summary
    In five patients in whom three-dimensional reconstruction images were analyzed, there were significant increases of bone volume and trabecular thickness, and a significant decrease in the trabecular bone pattern factor, a parameter related to the continuity, suggesting an improvement of the three-di…
  5. 05HumanNon-randomized trialEfficacy outcome

    In primary osteoporosis patients, three-dimensional analysis showed significantly increased trabecular thickness after hPTH.

    In plain wordsIn patients with primary osteoporosis, hPTH increased trabecular thickness compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTrabecular thickness
    Study

    n = 5

    Comparator
    Preadministration measurements
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 units once weekly · subcutaneous · 1 yearAs given in this study (human).

    Source sentences

    Summary
    In five patients in whom three-dimensional reconstruction images were analyzed, there were significant increases of bone volume and trabecular thickness, and a significant decrease in the trabecular bone pattern factor, a parameter related to the continuity, suggesting an improvement of the three-di…
  6. 06HumanNon-randomized trialEfficacy outcome

    In primary osteoporosis patients, hPTH significantly decreased the trabecular bone pattern factor in three-dimensional analysis.

    In plain wordsIn patients with primary osteoporosis, hPTH reduced a measure of disrupted bone connections compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTrabecular bone pattern factor
    Study

    n = 5

    Comparator
    Preadministration measurements
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 units once weekly · subcutaneous · 1 yearAs given in this study (human).

    Source sentences

    Summary
    In five patients in whom three-dimensional reconstruction images were analyzed, there were significant increases of bone volume and trabecular thickness, and a significant decrease in the trabecular bone pattern factor, a parameter related to the continuity, suggesting an improvement of the three-di…
  7. 07HumanNon-randomized trialEfficacy outcome

    In patients with primary osteoporosis, weekly hPTH increased lumbar bone mineral density progressively from baseline.

    In plain wordsIn patients with primary osteoporosis, weekly hPTH increased lumbar bone density compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar bone mineral density trajectory
    Study

    n: not reported in source

    Comparator
    Preadministration measurements
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 units once weekly · subcutaneous · 1 yearAs given in this study (human).

    Measurements

    LBMD increase
    1.8%
    12 weeks
    LBMD increase
    3.4%
    24 weeks
    LBMD increase
    4.6%
    48 weeks

    Source sentences

    Summary
    The mean lumbar bone mineral density (LBMD) definitely increased, by 1.8%, 3.4%, and 4.6% after 12, 24, and 48 weeks of hPTH administration, in accordance with previous clinical studies.
  8. 08HumanNon-randomized trialEfficacy outcome

    In primary osteoporosis patients, microstructural indices indicated improved trabecular continuity after hPTH.

    In plain wordsIn patients with primary osteoporosis, bone structure measurements indicated improved trabecular continuity after hPTH compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTrabecular continuity
    Study

    n: not reported in source

    Comparator
    Preadministration measurements
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 units once weekly · subcutaneous · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Indices of two-dimensional microstructure obtained by microfocus computed tomography (CT) and results of node-strut analysis indicated improvement of trabecular continuity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.